Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 480

Sort by

Sort Order Select

Journal Articles

Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group

Aleksandra Golos, MD PhD, Krzysztof Mądry, MD PhD, Karol Lis, Marta Sobas, MD, Agnieszka Ożańska, Magdalena Czemerska, Dorota Hawrylecka, Agnieszka Stelmach-Gołdyś, Karolina Chromik, Bartosz Pula, Ewa Lech-Maranda, MD PhD, Joanna Gora Tybor, MD PhD

Blood (2019) 134 (Supplement_1): 5422.

https://doi.org/10.1182/blood-2019-125711

Published: 2019

Journal Articles

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Antonis Patrinos, MD, Maria Melachrinou, MD PhD, Alexandra Kourakli, MD PhD, Vassiliki Pappa, MD, Maria K. Angelopoulou, MD, Anastasia Sioni, Nikolaos Kanellias, MD, Sofia Chatzileontiadou, MD, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, MD PhD, Maria Papaioannou, Evangelos Terpos, MD PhD, Gerasimos Pangalis, MD, Theodoros P. Vassilakopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5340.

https://doi.org/10.1182/blood-2019-130219

Published: 2019

Journal Articles

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

Cassidy Brothers, MD MSC

Blood (2019) 134 (Supplement_1): 5631.

https://doi.org/10.1182/blood-2019-125378

Published: 2019

Journal Articles

Flow-Cytometry Based Detection of Any Minimal Residual Disease (FC-MRD) in Children with T-Acute Lymphoblastic Leukemias (T-ALL) Is a Powerful Indicator of Outcome

Prashant Tembhare, MD, Gaurav Narula, MD, Gaurav Chatterjee, MD, Twinkle Khanka, Mahima Sanyal, Sitaram Ghogale, Nikhil Patkar, MD, Nilesh Deshpande, Yajamanam Badrinath, Sumeet Gujral, MD, Shripad Banavali, MD, Papagudi Ganesan Subramanian, MD

Blood (2019) 134 (Supplement_1): 2585.

https://doi.org/10.1182/blood-2019-128347

Published: 2019

Journal Articles

Comorbidities Reduce Response to Induction Treatment and Survival in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia

Ilaria Tanasi, Veronica Tagliaferri, Cristina Tecchio, Fiorenza Aprili, Giovanna De Matteis, Giovanni Pizzolo, Mauro Krampera, Massimiliano Bonifacio, MD

Blood (2019) 134 (Supplement_1): 2587.

https://doi.org/10.1182/blood-2019-130160

Published: 2019

Journal Articles

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients

Carrie I Ho, MD, Hatcher J. Ballard, BS, W. Tris Arscott, MD, Mitchell E. Hughes, PharmD, Abigail Doucette, MPH, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, James N. Gerson, MD, Amit Maity, MD PhD, Stephen J. Schuster, MD, Stefan K. Barta, MD MRCP, MS, John Plastaras, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 2905.

https://doi.org/10.1182/blood-2019-124195

Published: 2019

Journal Articles

Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience

Nikesh Shah, MD, Franco Castillo-Tokumori, MD, Julio C. Chavez, MD, Leidy Isenalumhe, MD, Hayder Saeed, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Javier Pinilla Ibarz, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 3991.

https://doi.org/10.1182/blood-2019-127291

Published: 2019

Journal Articles

Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) Registry Data

Blood (2019) 134 (Supplement_1): 4021.

https://doi.org/10.1182/blood-2019-129123

Published: 2019

Journal Articles

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Karin Ekstrom Ekstroem Smedby, Sara Ekberg, Sandra Eloranta, Gunilla Enblad, Mats Jerkeman, MD Professor, Per-Ola Andersson, MD PhD, Sara Harrysson, MD

Blood (2019) 134 (Supplement_1): 4111.

https://doi.org/10.1182/blood-2019-123785

Published: 2019

Journal Articles

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

Lakshman Vasanthamohan, MD FRCPC, Brent Parker, MD, Joy Mangel, MD FRCPC, Selay Lam, MDBSc,FRCPC, Kang Howson-Jan, MD FRCPC, Chai Wye Phua, MD FRCPC

Blood (2019) 134 (Supplement_1): 4131.

https://doi.org/10.1182/blood-2019-126997

Published: 2019

Journal Articles

Report on the Treatment of Hodgkin Lymphoma with ABVD Chemotherapy at Two Rural District Hospitals in Rwanda

Cyprien Shyirambere, MD, Rebecca Deboer, MD, Yvan Butera, MD, Caitlin Driscoll, resident, Jean Bosco Bigirimana, Francois Regis Uwizeye, Temidayo Fadelu, MD, Paul H Park, MD, Alan Paciorek, Leslie E. Lehmann, MD, Lawrence N. Shulman, MD

Blood (2019) 134 (Supplement_1): 4053.

https://doi.org/10.1182/blood-2019-130780

Published: 2019

Journal Articles

Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)

Qian Mei, PhD, Wenying Zhang, MD, Yang Liu, MD, Qingming Yang, MD, John E.J. Rasko, MBBS, PhD, Weidong Han, PhD MD

Blood (2019) 134 (Supplement_1): 4072.

https://doi.org/10.1182/blood-2019-121768

Published: 2019

Journal Articles

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Sunita Dwivedy Nasta, MD, Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Daniel J. Landsburg, MD, Elise A. Chong, MD, Stefan K. Barta, MD MRCP, MS, Noelle V. Frey, MD, James N. Gerson, MD, Amit Maity, MD PhD, John Plastaras, MD, David L. Porter, MD, Marco Ruella, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 4108.

https://doi.org/10.1182/blood-2019-131399

Published: 2019

Journal Articles

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Francesca Montanari, MD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Jennifer Kimberly Lue, MD, Enrica Marchi, MD, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 2909.

https://doi.org/10.1182/blood-2019-131841

Published: 2019

Journal Articles

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

James Yeung, MBBS, Ashlea Campbell, BSc MBBS FRACP FRCPA, Christian E Bryant, MBBS PhDFRACP FRCPA, Liane Khoo, MBBS PhDFRACP FRCPA, Scott Dunkley, MBBS FRACP FRCPA, Harry J Iland, MBBS FRACP FRCPA MHGSA, Stephen R Larsen, MBBS PhDFRACP FRCPA, Susan Moreton, MBBS FRACP FRCPA, Douglas E Joshua, BSc(Hons) MBBS DPhil FRACP FRCPA, Vinay Vanguru, MBBS FRACP FRCPA, Derek A McCulloch, BSc MBBChir PhDFRACP FRCPA, Danny Hsu, MBBS FRACP FRCPA, John Gibson, MBBS PhDFRACP FRCPA, P. Joy Ho, MBBS DPhil FRACP FRCPA, Christina Brown, MBBS PhDFRACP FRCPA

Blood (2019) 134 (Supplement_1): 2911.

https://doi.org/10.1182/blood-2019-131589

Published: 2019

Journal Articles

Real World Outcomes of Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation and Receive Commercially-Available Salvage Therapy

Emily C. Ayers, MD, David J Margolis, MD, Phyllis A. Gimotty, PhD, Daniel J. Landsburg, MD

Blood (2019) 134 (Supplement_1): 2893.

https://doi.org/10.1182/blood-2019-128815

Published: 2019

Journal Articles

Real World Population-Based Exploration of the Pathology Subtyping and Treatment-Modalities of Diffuse Large B-Cell Lymphoma in Belgium in Relation to Survival

Willem Daneels, MD, Michael Rosskamp, PhD, Gilles Macq, PhD, Estabraq Ismael Saadoon, MD, Anke De Geyndt, PhD, Fritz Offner, MD, Helene A. Poirel, MD PhD

Blood (2019) 134 (Supplement_1): 2894.

https://doi.org/10.1182/blood-2019-122443

Published: 2019

Journal Articles

Precision Medicine Based on the Achievement of Sustained Undetectable Minimal Residual Disease (MRD) By Next-Generation Flow (NGF) and Imaging Leads to Significant Reduction in Risk of Progression of Patients with Multiple Myeloma (MM)

Jose Enrique De La Puerta Rueda, MD, Leire Burgos, Garazi Letamendi Madariaga, MD, Cristina Martinez Bilbao, MD, Luis Atutxa Aresti, MD, Jesus Ojanguren Bergaz, MD, Matxalen Olivares Salaverri, MD, Begoña Sancho Garaizabal, MD, Isabel Uriarte, MD, Iñigo Vicente Olabarria, MD, Raquel Pérez Garay, MD, Ana de Juan Arroyo, Pharm, Itxaso Amarika Ibarrondo, MD, Tomas Carrascosa Vallejo, MD, Amaia Casado Diez, MD, Cristina Cortes Fernández, MD, Ianire Etxeguren Urkixo, MD, Eukene Gainza González, MD, Inés González Vallejo, MD, Javier Goikolea Ugarte, Pharm, Inmaculada Barredo Santamaría, MD, Alberto Sáiz López, MD, Antonio Vázquez Rodríguez, MD, Eloisa Urrechaga Igartua, MD, Maria José Ereño Ealo, MD, Estibalitz Montejo Rodrigo, MD, Elixabete Pastor Ausin, MD, Alberto Cabrera Zubizarreta, MD, José María Ontañón Garcés, MD, Ibone Saralegui Prieto, MD, Natalia Maruri Machado, MD, Paula Arana Berganza, MD, Mara Celis Alvarez, MD, Ane Aranbarri Larrañaga, MD, Paloma Ibarrondo Chamorro, MD, Bruno Paiva, PhD

Blood (2019) 134 (Supplement_1): 3170.

https://doi.org/10.1182/blood-2019-125062

Published: 2019

Journal Articles

MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy

Brandon Imber, MD MA, M. Lia Palomba, MD, Carl DeSelm, MD PhD, Connie Lee Batlevi, MD PhD, Parastoo B. Dahi, MD, Sergio A. Giralt, MD, Ariela Noy, MD, Jae H. Park, MD, Craig S. Sauter, MD, Michael Scordo, MD, Gunjan L. Shah, MDMS, Michel Sadelain, MD PhD, Miguel-Angel Perales, MD, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 3238.

https://doi.org/10.1182/blood-2019-131449

Published: 2019

Journal Articles

Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Therapy

Brandon Imber, MD MA, M. Lia Palomba, MD, Carl DeSelm, MD PhD, Parastoo B. Dahi, MD, Craig S. Sauter, MD, Michael Scordo, MD, Connie Lee Batlevi, MD PhD, Jae H. Park, MD, Gunjan L. Shah, MDMS, Sergio A. Giralt, MD, Miguel-Angel Perales, MD, Michel Sadelain, MD PhD, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 3244.

https://doi.org/10.1182/blood-2019-129620

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

Flow-Cytometry Based Detection of Any Minimal Residual Disease (FC-MRD) in Children with T-Acute Lymphoblastic Leukemias (T-ALL) Is a Powerful Indicator of Outcome

Comorbidities Reduce Response to Induction Treatment and Survival in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients

Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience

Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) Registry Data

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

Report on the Treatment of Hodgkin Lymphoma with ABVD Chemotherapy at Two Rural District Hospitals in Rwanda

Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

Real World Outcomes of Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation and Receive Commercially-Available Salvage Therapy

Real World Population-Based Exploration of the Pathology Subtyping and Treatment-Modalities of Diffuse Large B-Cell Lymphoma in Belgium in Relation to Survival

Precision Medicine Based on the Achievement of Sustained Undetectable Minimal Residual Disease (MRD) By Next-Generation Flow (NGF) and Imaging Leads to Significant Reduction in Risk of Progression of Patients with Multiple Myeloma (MM)

MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy

Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only